Following the expiration of the drug’s patent, three Indian pharmaceutical businesses have released generic forms of semaglutide injections, providing patients with cheaper alternatives for treating obesity and type 2 diabetes.

Following the debut in India of its generic semaglutide injection at Rs 1,290 per month, Natco Pharma, which is located in Hyderabad, launched its versions the next day. The businesses in question were Dr. Reddy’s Laboratories, Sun Pharma, and Zydus Lifesciences.

Semaglutide was introduced by Sun Pharma under the trade names Noveltreat and Sematrinity, with the former intended for long-term weight management and available in five different dose levels, while the latter was intended for type 2 diabetes that was not adequately managed and is offered in two different dose levels.

Reports indicate that the weekly treatment costs for Noveltreat vary between Rs 900 and Rs 2,000, while the costs for Sematrinity range between Rs 750 and Rs 1,300.

The semaglutide injection from Zydus Lifesciences was introduced in a reusable multi-dose pen gadget. According to reports, the average monthly treatment cost of the medicine, which is sold under the brand names SEMAGLYN, MASHEMA, and ALTERME, is about Rs 2,200. It is used to treat both obesity and type 2 diabetes.

Obeda, which Dr. Reddy’s Laboratories claims to be the first DCGI-approved generic semaglutide for Type 2 diabetes in India, was unveiled by the company. The medication is available in 2 mg and 4 mg pre-filled disposable pens for once-weekly usage, with a monthly cost of Rs 4,200 for both strengths.

Semaglutide belongs to the class of GLP-1 receptor agonists, which has been shown to help with weight management and glycemic control.

According to the Ministry of Commerce and Industry, India’s pharmaceutical exports increased by 9. 4% in 2024–25 to $30. 47 billion, and the industry is currently getting ready to grow in the double digits in 2026–27 with significant government assistance.

According to the ministry, the market for pharmaceuticals, which is currently worth about $60 billion, is expected to increase to $130 billion by 2030.

With the third-largest pharmaceutical production volume in the world, the nation exports its pharmaceuticals to over 200 nations.